深圳再添国家级名片，这一诊治示范中心在港大深圳医院揭牌

Core Viewpoint - The establishment of the "Standardized Diagnosis and Treatment Center - Systemic Lupus Erythematosus Demonstration Center" at Hong Kong University Shenzhen Hospital marks a significant advancement in the treatment and management of systemic lupus erythematosus (SLE) in Shenzhen and the Greater Bay Area, enhancing the hospital's capabilities and recognition in this field [1][3]. Group 1: Hospital Achievements - Hong Kong University Shenzhen Hospital is the first medical institution in Shenzhen to receive the national certification as a demonstration center for SLE, one of only 11 institutions nationwide [1]. - The hospital's rheumatology and immunology department has developed a high-quality professional team and established a standardized model covering prevention, diagnosis, and treatment of SLE, serving approximately 4,000 patient visits annually in recent years [2]. Group 2: Research and Development - The department has been actively involved in building a national rheumatology data center and a standardized biobank for SLE, laying a solid foundation for clinical research and scientific transformation [2]. - The introduction of innovative drugs, such as Abatacept, through the "Hong Kong-Macau Drug and Device Pass" policy provides new treatment options for moderate to severe active SLE patients [4]. Group 3: Future Plans and Impact - The hospital aims to leverage the demonstration center's establishment to enhance the standardization of SLE treatment, improve patient survival rates and quality of life, and contribute to the national efforts in managing autoimmune diseases [5][6]. - Future initiatives include the establishment of disease assessment scales, regular standardized evaluations, and enhanced training for healthcare professionals in local hospitals to improve overall treatment capabilities [6].